Selected Publications
Persaud Y, Shamoun M, Chitlur M, Des Rosier KJ, Taub JW. Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second "Hit" in Leukemogenesis. J Pediatr Hematol Oncol 43(8):e1241-e1243, 2021. doi:10.1097/MPH.0000000000002037
Persaud Y, Bagla S, Shanti CM, Shehata BM, Ravindranath Y, Gorsi HS. A novel finding in pediatric leiomyosarcoma: Expanding spectrum of FGFR rearrangements in childhood cancers. Pediatr Blood Cancer 68(4):e28805, 2021. doi:10.1002/pbc.28805
Persaud Y, Seddiq M, Wu YM, et al. Unusual clinical behavior of a very late retinoblastoma relapse in a patient with a germline RB mutation. Pediatr Blood Cancer 68(8):e29064, 2021. doi:10.1002/pbc.29064
Beydoun SB, Persaud Y, Lafferty J, Callaghan MU, Savaşan S. Bortezomib treatment of steroid-refractory Evans syndrome in children. Pediatr Blood Cancer 67(12):e28725, 2020. doi:10.1002/pbc.28725
Seddiq M, Gadgeel M, Persaud Y, Lafferty J, Savaşan S. Severe macrothrombocytopenia with platelet CD9 deficiency responsive to romiplostim. Br J Haematol 10.1111/bjh.16812, 2020. Epub Jun 8, 2020. doi:10.1111/bjh.16812
Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit DB. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 26;31(4):446-57, 2012.
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit, DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 23;480(7377):387-90, 2011.
Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci 107(33):14903-8, 2010.
Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB, Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 70(14):5901-11, 2010.
Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB., Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68(22):9375-83, 2008.
Last update: November 2021